FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969883409> ?p ?o ?g. }

• W2969883409 endingPage "2834" @default.
• W2969883409 startingPage "2834" @default.
• W2969883409 abstract "Introduction: Rituximab (R) plus chemotherapy (chemo) is standard of care for patients (pts) with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). A subcutaneous (SC) formulation of R (R-SC) that has a non-inferior pharmacokinetic profile to the intravenous (IV) formulation (R-IV) and similar efficacy and safety in DLBCL and FL pts is now available for clinical use. The randomized, open-label, crossover, Phase 3b PrefMab study (NCT01724021) aimed to explore pt preference and treatment satisfaction for the SC vs IV formulation of R. In the primary analysis (data cut-off, January 19, 2015; Rummel et al. Ann Oncol 2017), a strong pt preference for R-SC over R-IV administration was demonstrated (81% vs 11% at Cycle 8; primary endpoint). In addition, on the Rituximab Administration Satisfaction Questionnaire, median scores were higher for R-SC vs R-IV for 9Impact on Activities of Daily Living9, 9Convenience of Therapy9, 9Satisfaction with Therapy9, and 9Psychological Impact9. No new safety signals were reported. Here, we present the final analysis of the PrefMab study, which was performed after all pts had completed at least 24 months9 follow-up (data cut-off, December 20, 2016) with a focus on long-term pt outcomes and safety. Methods: Pts aged 18-80 yrs with previously untreated CD20+ DLBCL or FL were randomized 1:1 to receive one of two 8-cycle schedules of R in combination with 6-8 cycles of chemo (CHOP, CVP, or bendamustine, as per local practice): Sequence A (n=372), 1 cycle R-IV (375mg/m2) then 3 cycles R-SC (1400mg) then 4 cycles R-IV; Sequence B (n=371), 4 cycles R-IV then 4 cycles R-SC. Maintenance therapy was not mandated by the study protocol; however, pts with FL could receive maintenance at the investigator9s discretion. Secondary endpoints reported here include overall (OR) and complete response (CR) rates (assessed according to Cheson 1999 criteria) and investigator-assessed progression-free (PFS), event-free (EFS), disease-free, and overall survival. Safety was also assessed by treatment-emergent adverse event (AE) reporting. Efficacy was analyzed in all randomized pts, safety in all pts who received ≥1 dose of R. Results: Of 743 randomized pts, 740 received study treatment (465 pts with DLBCL [63%], 273 with FL [37%], and 2 other [0.3%]). Demographics and baseline characteristics are presented in Table 1. The median age of pts with DLBCL was 61 yrs and of pts with FL was 59 yrs. The majority of pts with DLBCL and FL received CHOP chemo (Table 1). OR rates were >90% in both DLBCL and FL pts (Table 2). CR rates were 55.1% in pts with DLBCL and 44.4% in pts with FL (Table 2). PFS rates at 3 yrs were 79% in DLBCL pts and 91% in FL pts. Other time-to-event endpoints are presented in Table 2. EFS was shorter in FL pts than DLBCL pts; however, because R maintenance was considered a non-protocol-specified anti-lymphoma therapy, FL pts were censored at the time of starting maintenance therapy. Treatment sequence had no impact on response rates or time-to-event endpoints. Pharmacokinetic serum-level data will be presented. Of pts who received ≥2 cycles of treatment, 653/712 (92%) experienced ≥1 AE on or after Cycle 2. AEs were generally balanced according to administration route and diagnosis, although a higher rate of grade ≥3 AEs and serious AEs occurred in DLBCL pts compared with FL (Table 3). Most AEs occurred in Cycle 1, during which all pts received R-IV (pts with AE in Cycle 1: Arm A, 71%; Arm B, 69%). No administration-related reactions (ARRs) occurred at a frequency of ≥2% in pts receiving R-SC or R-IV on or after Cycle 2. There were no differences in rates of ARRs according to IV or SC administration. FL pts were more likely to experience an ARR than DLBCL pts. At the end of the study, 104 pts had died (85 DLBCL; 19 FL). Fatal AEs related to R, according to the investigator9s judgment, included oropharyngeal candidiasis, pneumonia, septic shock, febrile neutropenia, and myocardial infarction (1 case each). Conclusions: In addition to the strong pt preference for SC dosing and improved satisfaction observed in the primary analysis, these findings confirm that R-SC is an efficacious and well-tolerated treatment option in DLBCL and FL pts. Overall, outcomes did not appear to be impacted by treatment sequence. Disclosures Rummel: Roche: Honoraria, Other: PrefMab is sponsored by F. Hoffmann-La Roche Ltd. Third-party Medical Writing assistance, under the direction of Mathias Rummel, was provided by Lynda McEvoy of Gardiner-Caldwell Communications, and was funded by F. Hoffmann-La Roche Ltd, Research Funding. Brugger: AstraZeneca: Employment, Equity Ownership. Re: Gilead: Membership on an entity9s Board of Directors or advisory committees. Task: Genentech: Employment, Equity Ownership. McIntyre: Roche: Employment, Equity Ownership. Meier: Roche: Employment. Osborne: Roche: Employment. Smith: Roche: Employment. Grigg: Roche: Other: Funding to attend ASH 2016." @default.
• W2969883409 created "2019-08-29" @default.
• W2969883409 creator A5011522631 @default.
• W2969883409 creator A5021123903 @default.
• W2969883409 creator A5030768360 @default.
• W2969883409 creator A5033911275 @default.
• W2969883409 creator A5042513487 @default.
• W2969883409 creator A5042780466 @default.
• W2969883409 creator A5051688433 @default.
• W2969883409 creator A5052765312 @default.
• W2969883409 creator A5058521062 @default.
• W2969883409 creator A5061061032 @default.
• W2969883409 creator A5064196229 @default.
• W2969883409 creator A5066034815 @default.
• W2969883409 creator A5090559016 @default.
• W2969883409 date "2017-12-07" @default.
• W2969883409 modified "2023-09-28" @default.
• W2969883409 title "Efficacy and Safety of Subcutaneous or Intravenous Administration of Rituximab in Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Final Results of the Randomized, Open-Label, Crossover, PrefMab Study" @default.
• W2969883409 doi "https://doi.org/10.1182/blood.v130.suppl_1.2834.2834" @default.
• W2969883409 hasPublicationYear "2017" @default.
• W2969883409 type Work @default.
• W2969883409 sameAs 2969883409 @default.
• W2969883409 citedByCount "0" @default.
• W2969883409 crossrefType "journal-article" @default.
• W2969883409 hasAuthorship W2969883409A5011522631 @default.
• W2969883409 hasAuthorship W2969883409A5021123903 @default.
• W2969883409 hasAuthorship W2969883409A5030768360 @default.
• W2969883409 hasAuthorship W2969883409A5033911275 @default.
• W2969883409 hasAuthorship W2969883409A5042513487 @default.
• W2969883409 hasAuthorship W2969883409A5042780466 @default.
• W2969883409 hasAuthorship W2969883409A5051688433 @default.
• W2969883409 hasAuthorship W2969883409A5052765312 @default.
• W2969883409 hasAuthorship W2969883409A5058521062 @default.
• W2969883409 hasAuthorship W2969883409A5061061032 @default.
• W2969883409 hasAuthorship W2969883409A5064196229 @default.
• W2969883409 hasAuthorship W2969883409A5066034815 @default.
• W2969883409 hasAuthorship W2969883409A5090559016 @default.
• W2969883409 hasConcept C126322002 @default.
• W2969883409 hasConcept C141071460 @default.
• W2969883409 hasConcept C143998085 @default.
• W2969883409 hasConcept C168563851 @default.
• W2969883409 hasConcept C197934379 @default.
• W2969883409 hasConcept C203092338 @default.
• W2969883409 hasConcept C2777058707 @default.
• W2969883409 hasConcept C2778559949 @default.
• W2969883409 hasConcept C2779338263 @default.
• W2969883409 hasConcept C2780653079 @default.
• W2969883409 hasConcept C2781442060 @default.
• W2969883409 hasConcept C71924100 @default.
• W2969883409 hasConcept C90924648 @default.
• W2969883409 hasConceptScore W2969883409C126322002 @default.
• W2969883409 hasConceptScore W2969883409C141071460 @default.
• W2969883409 hasConceptScore W2969883409C143998085 @default.
• W2969883409 hasConceptScore W2969883409C168563851 @default.
• W2969883409 hasConceptScore W2969883409C197934379 @default.
• W2969883409 hasConceptScore W2969883409C203092338 @default.
• W2969883409 hasConceptScore W2969883409C2777058707 @default.
• W2969883409 hasConceptScore W2969883409C2778559949 @default.
• W2969883409 hasConceptScore W2969883409C2779338263 @default.
• W2969883409 hasConceptScore W2969883409C2780653079 @default.
• W2969883409 hasConceptScore W2969883409C2781442060 @default.
• W2969883409 hasConceptScore W2969883409C71924100 @default.
• W2969883409 hasConceptScore W2969883409C90924648 @default.
• W2969883409 hasLocation W29698834091 @default.
• W2969883409 hasOpenAccess W2969883409 @default.
• W2969883409 hasPrimaryLocation W29698834091 @default.
• W2969883409 hasRelatedWork W2212055142 @default.
• W2969883409 hasRelatedWork W2287987606 @default.
• W2969883409 hasRelatedWork W2480694440 @default.
• W2969883409 hasRelatedWork W2550714334 @default.
• W2969883409 hasRelatedWork W2550958187 @default.
• W2969883409 hasRelatedWork W2551298659 @default.
• W2969883409 hasRelatedWork W2558112714 @default.
• W2969883409 hasRelatedWork W2559040579 @default.
• W2969883409 hasRelatedWork W2559637800 @default.
• W2969883409 hasRelatedWork W2560657755 @default.
• W2969883409 hasRelatedWork W2567287792 @default.
• W2969883409 hasRelatedWork W2575907824 @default.
• W2969883409 hasRelatedWork W2582014052 @default.
• W2969883409 hasRelatedWork W2584789089 @default.
• W2969883409 hasRelatedWork W2593648047 @default.
• W2969883409 hasRelatedWork W2901986266 @default.
• W2969883409 hasRelatedWork W2977809460 @default.
• W2969883409 hasRelatedWork W2980200289 @default.
• W2969883409 hasRelatedWork W3096116023 @default.
• W2969883409 hasRelatedWork W3209431811 @default.
• W2969883409 hasVolume "130" @default.
• W2969883409 isParatext "false" @default.
• W2969883409 isRetracted "false" @default.
• W2969883409 magId "2969883409" @default.
• W2969883409 workType "article" @default.